Strike Three As Novartis’s Ilaris Swings And Misses In Lung Cancer
Anti-Inflammatory Drug Fails In A Third Setting
The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.
